ChromaDex Corporation (CDXC) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
10900 WILSHIRE BLVD LOS ANGELES, CA 90024 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2833 - Medicinal Chemicals and Botanical Products (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 27,700 | 27,400 | 27,200 | 26,600 | 26,300 | 23,000 | |||
| Cash and cash equivalents | 27,700 | 27,400 | 27,200 | 26,600 | 26,300 | 23,000 | |||
| Receivables | 7,818 | 6,604 | (68) | (993) | (826) | 9,221 | |||
| Inventory, net of allowances, customer advances and progress billings | 11,511 | 12,495 | 14,525 | 12,624 | 11,973 | 11,908 | |||
| Inventory | 11,511 | 12,495 | 14,525 | 12,624 | 11,973 | 11,908 | |||
| Other undisclosed current assets | 2,273 | 2,477 | 7,877 | 8,950 | 8,935 | 2,436 | |||
| Total current assets: | 49,302 | 48,976 | 49,534 | 47,181 | 46,382 | 46,565 | |||
| Noncurrent Assets | |||||||||
| Operating lease, right-of-use asset | 2,063 | 2,226 | 2,400 | 3,003 | 3,179 | 3,352 | |||
| Intangible assets, net (including goodwill) | 435 | 472 | 510 | 552 | 591 | 630 | |||
| Intangible assets, net (excluding goodwill) | 435 | 472 | 510 | 552 | 591 | 630 | |||
| Regulated entity, other noncurrent assets | 68 | ||||||||
| Other noncurrent assets | 394 | 405 | 383 | 454 | 518 | 532 | |||
| Other undisclosed noncurrent assets | 1,841 | 2,000 | 2,069 | 2,293 | 2,501 | 2,689 | |||
| Total noncurrent assets: | 4,733 | 5,103 | 5,430 | 6,302 | 6,789 | 7,203 | |||
| TOTAL ASSETS: | 54,035 | 54,079 | 54,964 | 53,483 | 53,171 | 53,768 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 16,726 | 18,364 | 19,725 | 18,391 | 18,110 | 17,561 | |||
| Accounts payable | 8,105 | 7,899 | 10,232 | 9,198 | 10,031 | 8,951 | |||
| Accrued liabilities | 8,621 | 10,465 | 9,493 | 9,193 | 8,079 | 8,610 | |||
| Deferred revenue | 156 | 227 | 195 | 189 | 166 | 148 | |||
| Debt | 12 | 11 | 11 | 10 | 10 | 17 | |||
| Other undisclosed current liabilities | 973 | 850 | 691 | 854 | 775 | 697 | |||
| Total current liabilities: | 17,867 | 19,452 | 20,622 | 19,444 | 19,061 | 18,423 | |||
| Noncurrent Liabilities | |||||||||
| Long-term debt and lease obligation | 6 | 9 | 12 | 14 | 17 | 20 | |||
| Finance lease, liability | 6 | 9 | 12 | 14 | 17 | 20 | |||
| Liabilities, other than long-term debt | 5,444 | 5,667 | 5,874 | 6,717 | 6,943 | 7,308 | |||
| Deferred revenue | 3,311 | 3,311 | 3,311 | 3,806 | 3,806 | 3,955 | |||
| Operating lease, liability | 2,133 | 2,356 | 2,563 | 2,911 | 3,137 | 3,353 | |||
| Total noncurrent liabilities: | 5,450 | 5,676 | 5,886 | 6,731 | 6,960 | 7,328 | |||
| Total liabilities: | 23,317 | 25,128 | 26,508 | 26,175 | 26,021 | 25,751 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | 30,718 | 28,951 | 28,456 | 27,308 | 27,150 | 28,017 | |||
| Common stock | 75 | 75 | 75 | 75 | 75 | 74 | |||
| Additional paid in capital | 221,612 | 219,829 | 218,845 | 217,808 | 216,691 | 215,367 | |||
| Accumulated deficit | (190,967) | (190,952) | (190,460) | (190,574) | (189,615) | (187,424) | |||
| Other undisclosed equity, attributable to parent | (2) | (1) | (4) | (1) | (1) | ||||
| Total equity: | 30,718 | 28,951 | 28,456 | 27,308 | 27,150 | 28,017 | |||
| TOTAL LIABILITIES AND EQUITY: | 54,035 | 54,079 | 54,964 | 53,483 | 53,171 | 53,768 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 22,739 | 22,153 | 21,196 | 19,495 | 20,323 | 22,556 | ||
| Cost of revenue | (9,046) | (8,697) | (8,259) | (7,526) | (7,967) | (9,038) | ||
| Gross profit: | 13,693 | 13,456 | 12,937 | 11,969 | 12,356 | 13,518 | ||
| Operating expenses | (13,949) | (14,187) | (13,105) | (13,116) | (14,672) | (15,486) | ||
| Operating income (loss): | (256) | (731) | (168) | (1,147) | (2,316) | (1,968) | ||
| Net income (loss): | (256) | (731) | (168) | (1,147) | (2,316) | (1,968) | ||
| Other undisclosed net income attributable to parent | 241 | 239 | 282 | 188 | 125 | 66 | ||
| Net income (loss) available to common stockholders, diluted: | (15) | (492) | 114 | (959) | (2,191) | (1,902) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 9/30/2024 Q3 | 6/30/2024 Q2 | 3/31/2024 Q1 | 12/31/2023 Q4 | 9/30/2023 Q3 | 6/30/2023 Q2 | 3/31/2023 Q1 | ||
|---|---|---|---|---|---|---|---|---|
| Net income (loss): | (256) | (731) | (168) | (1,147) | (2,316) | (1,968) | ||
| Comprehensive income (loss), net of tax, attributable to parent: | (256) | (731) | (168) | (1,147) | (2,316) | (1,968) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.